Image Sourced ShutterStock
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • RotoGro is expanding its global presence following the purchase of Canadian company Supra THC and the distribution of its ‘Garden’ technology across North America, Europe and Australasia
  • RotoGro’s share price hasn’t changed from previous close. It currently sits at $0.15 per share.

RotoGro is focusing on increasing its global presence as a cultivator of legal cannabis.

Following the purchase of Canadian medical cannabis testers, Supra THC, the company is looking to expand its business.

Supra THC obtained a dealers license from Health Canada. The license gives the company approval to conduct standard processing, analytical testing, research, production and sales and distribution of lawful cannabis.

As RotoGro works to increase its presence in Canada, the company is looking at becoming dually listed on the Canadian Securities Exchange (CSE).

In addition the being listed on the ASX, RotoGro is also listed on Germany’s Frankfurt Stock Exchange.

According to the company, being listed on the CSE exposes it to the largest capital market for cannabis focused companies globally.

RotoGro’s Garden technology has been successful in reducing operation costs and improving product consistency.

The tech triples growing space while occupying the same space as a regular flat deck table, significantly increasing the amount of cannabis grown in a given time frame.

RotoGro receive revenue from selling its Garden technology to other companies growing cannabis and agricultural businesses.

The company’s technology is being delivered across North America, Europe and Australasia.

RotoGro’s share price hasn’t changed from previous close. It currently sits at $0.15 per share.

RGI by the numbers
More From The Market Online
Saccharomyces cerevisiae yeast, 3D illustration.

Tissue Repairs soars nearly 32% on TGA approval for wound healing gel

Biotech company Tissue Repair Ltd (ASX:TRP) has seen its share price rise more than 30% on news it had gained TGA (Therapeutic
The Market Online Video

Little Green Pharma (ASX:LGP) reports revenue increase in Q4 FY24

This interview discusses Little Green Pharma’s (ASX:LGP) record-breaking quarterly results for June 2024, highlighting a 12% increase in revenue and significant cash receipts.
Illustration representing big data technology.

Opyl forms JV with UK and US consortium to bring products to the world

Medical technology and AI company Opyl Ltd is set to form a joint venture with UK…
Ai gen brain scan

EMVision Medical successfully fabs first prototype of First Responder brain scan device – portable enough for a backpack

EMVision Medical Devices (ASX:EMV) has announced its successful fabrication of a portable on-the-spot brain scanning device.